Abstract
For the majority of patients, the LSP doses observed are well within those reported in the literature available. However the modelling does suggest that for patients with more advanced disease, often with more extensive pelvic nodal disease, who would be allocated higher treatment doses in ACT5, there may be clinical consequences. It would seem prudent to not only contour the LSP in these patients to know the radiation doses their LSP is receiving.
Original language | English |
---|---|
DOIs | |
Publication status | Published - 20 Apr 2018 |
Event | European Society for Therapeutic Radiotherapy & Oncology Annual Meeting - Barcelona, Spain Duration: 20 Apr 2018 → 24 Apr 2018 Conference number: 37 |
Conference
Conference | European Society for Therapeutic Radiotherapy & Oncology Annual Meeting |
---|---|
Abbreviated title | ESTRO 37 |
Country/Territory | Spain |
City | Barcelona |
Period | 20/04/18 → 24/04/18 |
Keywords
- lumbrosacral plexus
- VMAT; dose volume histograms
- ACT 5; anal cancer